We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Rapid Influenza Detection Tests Evaluated for Viral Antigens

By LabMedica International staff writers
Posted on 01 Dec 2016
Reverse transcriptase polymerase chain reaction (RT-PCR) has a high sensitivity and a high specificity for the rapid diagnosis of influenza infection; however, the high cost and necessity of specialized equipment have limited the use of RT-PCR in the clinical setting.

Immunochromatography-based rapid influenza virus antigen tests, in which the result appears within 15 minutes, have been used for the early diagnosis of influenza in the clinical setting in Japan. More...
Rapid influenza detection tests (RIDTs) equipped with an instrument-based fluorescence reader system has recently been developed, and their performances have been validated.

Scientists at the Tokyo Medical University (Japan) enrolled a total of 123 participants consisting of 53 men (43.1%) and 70 women (56.9%). The mean age of the patients was 35.1 years (range 20–74 years). The median time to visiting the hospital after illness onset was 26.2 hours (ranging from a few hours to five days). The study was performed from December 2013 to March 2014. Nasopharyngeal swab specimens were collected by performing original swab samplings, which were composed of three swabs.

After collecting the specimens from the participants, the swabs were separated for the tests. One swab was transferred in viral transport medium for virus isolation; the other two swabs were used for the rapid influenza virus antigen detection tests. In this study, the new RIDT GOLD SIGN FLU (Morinaga Milk Industry Co., Ltd, Tokyo, Japan) and Institute of Immunology Co., Ltd, Tokyo, Japan) and the existing immunochromatography-based RIDT Quick Navi-Flu (Otsuka Pharmaceutical Co., Ltd, Tokyo, Japan) were evaluated as compared to viral isolation as the gold standard method.

Among the 123 patients from whom nasopharyngeal swab specimens were collected, 59 tested positive by viral isolation as the gold standard method, 38 with influenza A; 21 with influenza B. For GOLD SIGN FLU, the sensitivities were 73.7% and 81.0%, and the specificities were 97.6% and 98.0% for influenza A and B, respectively. For Quick Navi-Flu, the sensitivities were 86.8% and 85.7%, and the specificities were 98.8% and 100% for influenza A and B, respectively. The time to the appearance of the line on the test strip was less than three minutes for influenza A and less than two minutes for influenza B with both RIDTs in more than 90% of cases.

The authors concluded that GOLD SIGN FLU was useful for diagnosing influenza A, and the result was readily available for influenza B particularly among adult patients. Quick Navi-Flu showed better sensitivities and specificities than GOLD SIGN FLU. The study was published in the November 2016 issue of the International Journal of Infectious Diseases.

Related Links:
Tokyo Medical University
Morinaga Milk Industry
Institute of Immunology
Otsuka Pharmaceutical

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.